Human electrophysiological and pharmacological properties of XEN-D0101: A novel atrial-selective Kv1.5/IKur inhibitor

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 5, 2013, Pages 408-415

  Ford, John ^a   Milnes, James ^a   Wettwer, Erich ^b   Christ, Torsten ^b   Rogers, Marc ^a   Sutton, Kathy ^a   Madge, David ^a   Virag, Laszlo ^c   Jost, Norbert ^c,d   Horvath, Zoltan ^d   Matschke, Klaus ^e   Varro, Andras ^c,d   Ravens, Ursula ^b  

^a Xention Limited   (United Kingdom)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Department of Pharmacology and Pharmacotherapy ^*  (Hungary)

^d UNIVERSITY OF SZEGED   (Hungary)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.5; UNCLASSIFIED DRUG; XEN D 0101;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALE; POTASSIUM CURRENT; PRIORITY JOURNAL;

ACTION POTENTIALS; ATRIAL FIBRILLATION; ATRIAL FUNCTION; CELL LINE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; HEART ATRIA; HUMANS; KV1.5 POTASSIUM CHANNEL; MALE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; PYRIMIDINES; THIOPHENES; VENTRICULAR FUNCTION;

EID: 84877590480     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31828780eb     Document Type: Article

References (21)

1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360-1420.
2. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 2002; 415:219-226.
3. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719-728.
4. Camm AJ, Savelieva I. Advances in antiarrhythmic drug treatment of atrial fibrillation: where do we stand now? Heart Rhythm. 2004;1:244-246.
5. Waldo AL. A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need. Am Heart J. 2006;151:771-778.
6. Wang Z, Fermini B, Nattel S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res. 1993;73: 1061-1076.
7. Fedida D, Wible B, Wang Z, et al. Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circ Res. 1993;73:210-216.
8. Feng J, Wible B, Li GR, et al. Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ Res. 1997;80:572-579.
9. Ravens U, Wettwer E. Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications. Cardiovasc Res. 2011;89:776-785.
10. Amos GJ, Wettwer E, Metzger F, et al. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol. 1996;491(pt 1):31-50.
11. Li GR, Feng J, Yue L, et al. Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res. 1996;78: 689-696.
12. Nattel S. Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res. 2002;54:347-360.
13. Christ T, Wettwer E, Voigt N, et al. Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br J Pharmacol. 2008;154:1619-1630.
14. Ford JW, Milnes JT. New drugs targeting the cardiac ultra-rapid delayedrectifier current (IKur): rationale, pharmacology and evidence for potential therapeutic value. J Cardiovasc Pharmacol. 2008;52:105-120.
15. de Haan S, Greiser M, Harks E, et al. AVE0118, blocker of the transient outward current (Ito) and ultrarapid delayed rectifier current (IKur), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation. 2006;114:1234-1242.
16. Malik M, Hnatkova K, Ford J, et al. Near-thorough QT study as part of a first-in-man study. J Clin Pharmacol. 2008;48:1146-1157.
17. Dobrev D, Graf E, Wettwer E, et al. Molecular basis of down-regulation of G-protein-coupled inward rectifying K+ current IK, ACh in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced IK, ACh and muscarinic receptor-mediated shortening of action potentials. Circulation. 2001;104:2551-2557.
18. Wettwer E, Hála O, Christ T, et al. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation. 2004;110:2299-2306.
19. Dobrev D, Ravens U. Electrical remodeling of cardiomyocyte ion channels in human atrial fibrillation. Basic Res Cardiol. 2003;98:137-148.
20. Schotten U, de Haan S, Verheule S, et al. Blockade of atrial-specific K+- currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange. Cardiovasc Res. 2007;73:37-47.
21. Olson TM, Alekseev AE, Liu XK, et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet. 2006;15:2185-2191.